Drug intelligence / Profile preview

aspirin + flurbiprofen

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

A combination of two nonsteroidal anti-inflammatory drugs (NSAIDs) that work by blocking specific substances in the body that cause pain, inflammation, and fever. When administered together, aspirin can lower serum flurbiprofen concentrations, though clinical efficacy may remain unchanged. This combination is generally not recommended due to potential increased adverse effects and bleeding risk. Cross-sensitivity between aspirin and flurbiprofen has been demonstrated in patients with rhinosinusitis and asthma.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on aspirin + flurbiprofen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aspirin + flurbiprofen.

Explore the full profile